These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29252123)

  • 1. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.
    Molenaar RJ; Sidana S; Radivoyevitch T; Advani AS; Gerds AT; Carraway HE; Angelini D; Kalaycio M; Nazha A; Adelstein DJ; Nasr C; Maciejewski JP; Majhail NS; Sekeres MA; Mukherjee S
    J Clin Oncol; 2018 Jun; 36(18):1831-1839. PubMed ID: 29252123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
    Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
    Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
    Pasqual E; Schonfeld S; Morton LM; Villoing D; Lee C; Berrington de Gonzalez A; Kitahara CM
    J Clin Oncol; 2022 May; 40(13):1439-1449. PubMed ID: 35044839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.
    Molenaar RJ; Pleyer C; Radivoyevitch T; Sidana S; Godley A; Advani AS; Gerds AT; Carraway HE; Kalaycio M; Nazha A; Adelstein DJ; Nasr C; Angelini D; Maciejewski JP; Majhail N; Sekeres MA; Mukherjee S
    Leukemia; 2018 Apr; 32(4):952-959. PubMed ID: 29104287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
    Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
    Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population-based study.
    Mo X; Zhou M; Yan H; Chen X; Wang Y
    Cancer Med; 2021 Aug; 10(15):5338-5346. PubMed ID: 34189859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients.
    Mei X; Yao X; Feng F; Cheng W; Wang H
    BMC Cancer; 2021 May; 21(1):543. PubMed ID: 33980182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?
    Souza MC; Momesso DP; Vaisman F; Vieira Neto L; Martins RA; Corbo R; Vaisman M
    Arch Endocrinol Metab; 2016 Feb; 60(1):9-15. PubMed ID: 26222230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multilevel Factors Associated With More Intensive Use of Radioactive Iodine for Low-Risk Thyroid Cancer.
    Wallner LP; Banerjee M; Reyes-Gastelum D; Hamilton AS; Ward KC; Lubitz C; Hawley ST; Haymart MR
    J Clin Endocrinol Metab; 2021 May; 106(6):e2402-e2412. PubMed ID: 33687063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
    Reinecke MJ; Ahlers G; Burchert A; Eilsberger F; Flux GD; Marlowe RJ; Mueller HH; Reiners C; Rohde F; van Santen HM; Luster M
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3247-3256. PubMed ID: 35320386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
    Bhattacharyya N; Chien W
    Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.
    Reiners C; Schneider R; Platonova T; Fridman M; Malzahn U; Mäder U; Vrachimis A; Bogdanova T; Krajewska J; Elisei R; Vaisman F; Mihailovic J; Costa G; Drozd V
    Front Endocrinol (Lausanne); 2020; 11():381. PubMed ID: 32754115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer.
    Wu JX; Young S; Ro K; Li N; Leung AM; Chiu HK; Harari A; Yeh MW
    Thyroid; 2015 Jan; 25(1):133-8. PubMed ID: 25289542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland.
    Nixon IJ; Whitcher MM; Palmer FL; Tuttle RM; Shaha AR; Shah JP; Patel SG; Ganly I
    Thyroid; 2012 Sep; 22(9):884-9. PubMed ID: 22827579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
    Marti JL; Jain KS; Morris LG
    Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
    Zevallos JP; Xu L; Yiu Y
    Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS; Zanella AB; Dora JM; Maia AL
    Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult.
    Zhao X; Chen M; Qi X; Zhu H; Yang G; Guo Y; Dong Q; Yang Q
    Front Endocrinol (Lausanne); 2021; 12():805194. PubMed ID: 35154006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility Study Shows Multicenter, Observational Case-Control Study Is Practicable to Determine Risk of Secondary Breast Cancer in Females With Differentiated Thyroid Carcinoma Given Radioiodine Therapy in Their Childhood or Adolescence; Findings Also Suggest Possible Fertility Impairment in Such Patients.
    Drozd V; Schneider R; Platonova T; Panasiuk G; Leonova T; Oculevich N; Shimanskaja I; Vershenya I; Dedovich T; Mitjukova T; Grelle I; Biko J; Reiners C
    Front Endocrinol (Lausanne); 2020; 11():567385. PubMed ID: 33193085
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.